TITLE

Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer

AUTHOR(S)
Daudi, Sayeema; Eng, Kevin H.; Mhawech-Fauceglia, Paulette; Morrison, Carl; Miliotto, Anthony; Beck, Amy; Matsuzaki, Junko; Tsuji, Takemasa; Groman, Adrienne; Gnjatic, Sacha; Spagnoli, Guillo; Lele, Shashikant; Odunsi, Kunle
PUB. DATE
August 2014
SOURCE
PLoS ONE;Aug2014, Vol. 9 Issue 8, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The MAGE cancer-testis antigens (CTA) are attractive candidates for immunotherapy. The aim of this study was to determine the frequency of expression, humoral immunity and prognostic significance of MAGE CTA in human epithelial ovarian cancer (EOC). mRNA or protein expression frequencies were determined for MAGE-A1, -A3, -A4, -A10 and -C1 (CT7) in tissue samples obtained from 400 patients with EOC. The presence of autologous antibodies against the MAGE antigens was determined from 285 serum samples. The relationships between MAGE expression, humoral immunity to MAGE antigens, and clinico-pathologic characteristics were studied. The individual frequencies of expression were as follows: A1: 15% (42/281), A3: 36% (131/390), A4: 47% (186/399), A10: 52% (204/395), C1: 16% (42/267). Strong concordant expression was noted with MAGE-A1:–A4, MAGE-A1:–C1 and MAGE-A4:–A10 (p<0.0005). Expression of MAGE-A1 or -A10 antigens resulted in poor progression free survival (PFS) (OR 1.44, CI 1.01–2.04, p = 0.044 and OR 1.3, CI 1.03–1.64, p = 0.03, respectively); whereas, MAGE-C1 expression was associated with improved PFS (OR 0.62, CI 0.42–0.92, p = 0.016). The improved PFS observed for MAGE-C1 expression, was diminished by co-expression of MAGE-A1 or -A10. Spontaneous humoral immunity to the MAGE antigens was present in 9% (27/285) of patients, and this predicted poor overall survival (log-rank test p = 0.0137). These findings indicate that MAGE-A1, MAGE-A4, MAGE-A3, and MAGE-A10 are priority attractive targets for polyvalent immunotherapy in ovarian cancer patients.
ACCESSION #
97801409

 

Related Articles

  • Melanoma as a model tumour for immuno-oncology. Maio, M. // Annals of Oncology;Sep2012 Supplement 8, Vol. 23 Issue suppl_8, pviii10 

    Melanoma is one of the most aggressive forms of skin cancer. Furthermore, incidence rates are increasing. Until recently, no agent had been shown to improve survival over supportive care and treatment guidelines recommended that patients with metastatic disease were entered into clinical trials....

  • IOR C2: A TUMOR ASSOCIATED ANTIGEN AS POTENTIAL TARGET FOR IMMUNOTHERAPY IN EPITHELIAL OVARIAN CANCER. Cedeño-Arias, M.; Rengifo, C. E.; Ramos-Suzarte, M.; Santana, R. Blanco; Rengifo, E.; Nogales, F. F. // Acta Microscopica;2013, Vol. 22 Issue 3, p239 

    Ovarian cancer ranks the most lethal among gynecologic neoplasms in women. To assess the immunohistochemical expression of IOR C2 antigen in normal tissues as well as in ovarian cancer, the immunohistochemical expression of IOR C 2 in two ovarian cancer cell lines, frozen tissues from both fetus...

  • Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients. Wilkinson, Ray; Woods, Katherine; D'Rozario, Rachael; Prue, Rebecca; Vari, Frank; Hardy, Melinda; Dong, Ying; Clements, Judith; Hart, Derek; Radford, Kristen // Cancer Immunology, Immunotherapy;Feb2012, Vol. 61 Issue 2, p169 

    Immunotherapy is a promising new treatment for patients with advanced prostate and ovarian cancer, but its application is limited by the lack of suitable target antigens that are recognized by CD8 cytotoxic T lymphocytes (CTL). Human kallikrein 4 ( KLK4) is a member of the kallikrein family of...

  • Tenth International Conference on Progress in Vaccination Against Cancer (PIVAC 10), Cambridge, UK, 27th-30th September 2010: New hopes and strategies for cancer vaccines. McArdle, Stephanie; Rees, Robert // Cancer Immunology, Immunotherapy;Aug2011, Vol. 60 Issue 8, p1207 

    The Progress in Vaccination against Cancer (PIVAC) series of conferences celebrated 10 years of existence by returning to Cambridge, where the first meeting was held in the year 2001. This year, the conference at St Catharine's college was full of hope for the future of immunotherapy against...

  • Ovarian Cancer from an Immune Perspective. Zakharia, Yousef; Rahma, Osama; Khleif, Samir N. // Radiation Research;Aug2014, Vol. 182 Issue 2, p239 

    Despite major advances in the treatment of ovarian cancer over the past two decades, it is still an incurable disease and requires the development of better treatment strategies. In recent years, we have developed a greater understanding of tumor immunology and the interactions between tumors...

  • Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients. Inaoka, Riguel; Jungbluth, Achim; Gnjatic, Sacha; Ritter, Erika; Hanson, Nicole; Frosina, Denise; Tassello, Jodie; Etto, Leina; Bortoluzzo, Adriana; Alves, Antonio; Colleoni, Gisele // Cancer Immunology, Immunotherapy;Dec2012, Vol. 61 Issue 12, p2207 

    Background: Based on their tumor-associated expression pattern, cancer/testis antigens (CTAs) are considered potential targets for cancer immunotherapy. We aim to evaluate the expression of CTAs in non-Hodgkin's lymphoma (NHL) samples and the ability of these patients to elicit spontaneous...

  • Coordinated tumor immunity. Dranoff, Glenn // Journal of Clinical Investigation;4/15/2003, Vol. 111 Issue 8, p1116 

    Presents insights on cancer tumor immunology. Significance of the development of identification techniques for tumor antigens; Characterization of cancer cell antigenicity; Role of immunity in tumor suppression and progression.

  • Do cancer antigens rise en masse? Donaldson Jr., Robert M.; Berkowitz, Henry D. // Cortlandt Forum;7/25/95, Vol. 8 Issue 7, p115 

    Reports on the possibility that all cancer antigens along with the specific antigen rise when cancer occurs.

  • Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay. Akiyama, Yasuto; Komiyama, Masaru; Nakamura, Yoji; Iizuka, Akira; Oshita, Chie; Kume, Akiko; Nogami, Masahiro; Miyata, Haruo; Ashizawa, Tadashi; Yoshikawa, Shusuke; Kiyohara, Yoshio; Yamaguchi, Ken // Cancer Immunology, Immunotherapy;Dec2012, Vol. 61 Issue 12, p2311 

    Many cancer-testis antigen genes have been identified; however, few human leukocyte antigen (HLA)-A24-restricted cytotoxic T cell (CTL) epitope peptides are available for clinical immunotherapy. To solve this problem, novel tools increasing the efficacy and accuracy of CTL epitope detection are...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics